Profile data is unavailable for this security.
About the company
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
- Revenue in USD (TTM)55.02m
- Net income in USD-30.20m
- Incorporated2017
- Employees50.00
- LocationAvadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
- Phone+353 14851200
- Fax+353 15261077
- Websitehttps://www.avadel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Satsuma Pharmaceuticals Inc | 0.00 | -37.13m | 434.74m | 20.00 | -- | 4.18 | -- | -- | -2.16 | -2.16 | 0.00 | 5.98 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0411 | -- | -- | -- | -283.54 | -- | -- | -- |
| Rigel Pharmaceuticals, Inc. | 108.04m | -25.02m | 439.22m | 163.00 | -- | 6.95 | -- | 4.07 | -0.1494 | -0.1494 | 0.6427 | 0.3742 | 0.7345 | 0.6346 | 11.58 | 662,815.90 | -17.01 | -54.29 | -21.66 | -69.95 | 99.15 | -- | -23.16 | -213.28 | 3.21 | -- | 0.2387 | -- | 33.20 | 48.36 | 5.09 | -- | 28.64 | -- |
| Liminal BioSciences Inc | 2.80m | -173.86m | 439.38m | 300.00 | 1.39 | 7.41 | -- | 156.71 | 13.41 | 14.44 | 0.1416 | 2.51 | 0.0272 | 0.2668 | 1.04 | 9,345.82 | -169.21 | -72.42 | -210.96 | -93.80 | 38.10 | 51.09 | -6,218.73 | -694.98 | 2.39 | -19.19 | 0.3899 | -- | -80.09 | -26.59 | -18.19 | -- | -13.21 | -- |
| Catalyst Pharmaceuticals Inc | 119.76m | 41.77m | 441.12m | 76.00 | 10.90 | -- | 10.54 | 3.68 | 0.3912 | 0.3912 | 1.12 | -- | 1.14 | 16.28 | 13.98 | 1,575,806.00 | 39.84 | -18.06 | 47.66 | -20.19 | 85.74 | -- | 34.87 | -57.24 | 6.40 | -- | 0.00 | -- | 20,361.27 | -- | 193.74 | -- | -19.51 | -- |
| XBiotech Inc | 12.68m | 674.48m | 450.97m | 63.00 | 1.66 | 1.30 | 0.6663 | 35.56 | 9.40 | 9.40 | 0.2736 | 12.03 | 0.0637 | -- | -- | 211,350.00 | 338.77 | 72.46 | 350.27 | 78.04 | 23.71 | -- | 5,318.82 | -- | -- | -- | 0.00 | 0.00 | -- | -- | 3,263.16 | -- | -31.94 | -- |
| CEL-SCI Corporation | 519.81k | -31.44m | 452.74m | 43.00 | -- | 36.79 | -- | 870.96 | -0.9118 | -0.9118 | 0.015 | 0.327 | 0.0175 | -- | 5.60 | -- | -105.66 | -88.53 | -128.95 | -119.93 | -- | -- | -6,044.45 | -5,871.52 | 2.84 | -2.69 | 0.5197 | -- | -2.90 | 11.88 | 30.51 | -- | 11.32 | -- |
| Clovis Oncology Inc | 159.36m | -385.16m | 454.69m | 484.00 | -- | -- | -- | 2.85 | -6.07 | -6.07 | 2.44 | -1.10 | 0.2425 | 1.47 | 9.49 | 329,258.30 | -58.62 | -48.66 | -70.32 | -56.26 | 75.40 | -- | -241.69 | -562.83 | 2.63 | -14.24 | 1.20 | -- | 49.92 | 60.03 | -8.81 | -- | 7.55 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.02m | -30.20m | 456.31m | 50.00 | -- | 11.36 | -- | 8.29 | -0.7835 | -0.5613 | 1.44 | 0.691 | 0.2886 | 2.91 | 5.10 | 1,100,420.00 | -15.84 | -5.95 | -19.01 | -8.13 | 79.43 | 89.29 | -54.88 | -9.64 | 3.94 | -1.13 | 0.7936 | -- | -42.66 | 31.65 | 65.24 | -- | -55.85 | -- |
| Rubius Therapeutics Inc | 0.00 | -179.36m | 457.10m | 195.00 | -- | 1.94 | -- | -- | -2.26 | -2.26 | 0.00 | 2.92 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -48.36 | -- | -- | -- | -- | -- | -- | -- | 0.1744 | -- | -- | -- | -83.26 | -- | -- | -- |
| BioDelivery Sciences International, Inc. | 136.80m | 5.79m | 463.29m | 178.00 | 87.15 | 5.46 | 31.05 | 3.39 | 0.0527 | 0.0527 | 1.34 | 0.8401 | 0.7085 | 1.70 | 3.75 | 768,556.20 | 3.00 | -30.53 | 4.01 | -42.44 | 82.74 | 73.97 | 4.23 | -50.79 | 2.49 | 3.04 | 0.4801 | -- | 100.20 | 23.39 | 66.99 | -- | -45.23 | -- |
| DURECT Corporation | 50.07m | -1.83m | 469.35m | 89.00 | -- | 12.91 | -- | 9.37 | -0.0131 | -0.0131 | 0.2540 | 0.1812 | 0.7543 | 1.21 | 24.19 | 556,300.00 | -2.76 | -41.31 | -3.27 | -60.36 | 91.36 | 81.42 | -3.66 | -81.85 | 5.47 | -0.4074 | 0.3611 | -- | 59.25 | 8.79 | 18.73 | -- | -5.35 | -- |
| CymaBay Therapeutics Inc | 0.00 | -92.82m | 475.29m | 24.00 | -- | 2.72 | -- | -- | -1.35 | -1.35 | 0.00 | 2.54 | 0.00 | -- | -- | 0.00 | -40.12 | -51.60 | -42.54 | -59.81 | -- | -- | -- | -2,451.13 | -- | -- | 0.00 | -- | -- | -- | -41.71 | -- | 25.05 | -- |
| AC Immune SA | 52.60m | -26.93m | 481.46m | 115.00 | -- | 1.76 | -- | 9.15 | -0.3763 | -0.3763 | 0.7309 | 3.81 | 0.1691 | -- | 99.20 | 457,405.00 | -8.66 | -2.57 | -9.08 | -2.76 | -- | -- | -51.20 | -9.34 | -- | -128.15 | 0.0093 | -- | 1,443.31 | 29.68 | 189.19 | 33.43 | 71.25 | -- |
| AnaptysBio Inc | 18.00m | -81.11m | 481.99m | 89.00 | -- | 1.26 | -- | 26.78 | -2.99 | -2.99 | 0.6619 | 13.98 | 0.0408 | -- | -- | 202,247.20 | -18.39 | -16.74 | -19.52 | -17.79 | -- | -- | -450.59 | -347.09 | -- | -- | 0.00 | -- | 60.00 | -12.77 | -57.87 | -- | 40.89 | -- |
Data as of Aug 11 2020. Currency figures normalised to Avadel Pharmaceuticals PLC's reporting currency: US Dollar USD
32.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 15 Apr 2020 | 4.62m | 7.94% |
| Avoro Capital Advisor LLCas of 15 Apr 2020 | 3.90m | 6.70% |
| Acuta Capital Partners LLCas of 31 Mar 2020 | 2.67m | 4.60% |
| Brandes Investment Partners LPas of 31 Mar 2020 | 1.64m | 2.82% |
| Cowen & Co. LLCas of 31 Mar 2020 | 1.52m | 2.61% |
| VHCP Management LLCas of 31 Mar 2020 | 1.06m | 1.82% |
| Broadfin Capital LLCas of 31 Dec 2019 | 1.03m | 1.77% |
| Renaissance Technologies LLCas of 31 Mar 2020 | 905.81k | 1.56% |
| Invesco Advisers, Inc.as of 31 Mar 2020 | 733.01k | 1.26% |
| DWS Investment Management Americas, Inc.as of 31 Mar 2020 | 588.31k | 1.01% |
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
